Valuation: Adocia

Market Cap 73.18M 83.66M 67.5M 62.34M 118M 7.98B 120M 806M 317M 3.93B 314M 307M 13.51B P/E 2026 *
15.1x
P/E 2027 * 7.51x
Enterprise Value 43.33M 49.54M 39.97M 36.92M 70.05M 4.72B 71.22M 478M 188M 2.33B 186M 182M 8B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 3.2x
Free-Float
89.7%
Yield 2026 *
-
Yield 2027 * -
1 week-12.91%
Current month-9.90%
1 month-6.81%
3 months-22.04%
6 months-37.81%
Current year-42.75%
1 week 3.75
Extreme 3.75
4.36
1 month 3.75
Extreme 3.75
4.61
Manager TitleAgeSince
Chief Executive Officer 55 2023-05-10
Director of Finance/CFO - 2024-09-22
Chief Tech/Sci/R&D Officer - 2014-11-30
Director TitleAgeSince
Chairman 80 2012-02-23
Director/Board Member 58 2013-06-17
Director/Board Member 57 2021-05-20
Change 5-day change 1-year change 3-year change Capi.($)
-4.29%-8.20%-1.96% - 87.9M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%-0.66%+75.79%+93.87% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
-1.05%+1.16%+25.08%+196.28% 14.35B
+8.74%+3.51%+53.81% - 14.13B
Average -0.67%+0.26%+48.68%+148.68% 26.91B
Weighted average by Cap. -1.02%-1.11%+54.66%+138.25%

Financials

2026 *2027 *
Net sales 12.5M 14.29M 11.53M 10.65M 20.21M 1.36B 20.55M 138M 54.1M 671M 53.66M 52.49M 2.31B 32.26M 36.88M 29.75M 27.48M 52.14M 3.52B 53.02M 355M 140M 1.73B 138M 135M 5.96B
Net income -518K -592K -478K -441K -837K -56.46M -851K -5.71M -2.24M -27.82M -2.22M -2.17M -95.63M -47.3M -54.08M -43.63M -40.3M -76.47M -5.16B -77.75M -521M -205M -2.54B -203M -199M -8.74B
Net Debt -29.84M -34.12M -27.53M -25.42M -48.24M -3.25B -49.05M -329M -129M -1.6B -128M -125M -5.51B 30.18M 34.5M 27.83M 25.71M 48.78M 3.29B 49.6M 333M 131M 1.62B 130M 127M 5.57B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
26-07-10 €3.750 -4.29%
26-07-09 €3.918 +2.14%
26-07-08 €3.836 -3.47%
26-07-07 €3.974 -6.19%
26-07-06 €4.236 -1.63%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.740EUR
Average target price
10.70EUR
Spread / Average Target
+186.10%

Quarterly revenue - Rate of surprise